Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary …

Introduction Amyotrophic lateral sclerosis (ALS) is a fatal neurogenerative disease with no
effective treatment to date. Despite numerous clinical trials, the majority of studies have been …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that
severely impacts affected persons' speech and motor functions, yet early detection and …

Background Enhanced glutamatergic transmission leading to motor neuron death is
considered the major pathophysiological mechanism of amyotrophic lateral sclerosis (ALS) …

Identifying groups of patients with similar disease progression patterns is key to understand
disease heterogeneity, guide clinical decisions and improve patient care. In this paper, we …

Preclinical studies are crucial for developing amyotrophic lateral sclerosis drugs. Current
FDA-approved drugs have been created by monitoring limb muscle function and histological …

Background Oral tauroursodeoxycholic acid (TUDCA) is a commercial drug currently tested
in patients with amyotrophic lateral sclerosis (ALS) both singly and combined with sodium …

Amyotrophic lateral sclerosis, a progressive neurodegenerative disease, presents
challenges in predicting individual disease trajectories due to its heterogeneous nature. This …

Objective One of the difficulties in developing a novel drug for patients with amyotrophic
lateral sclerosis (ALS) is the significant variation in the clinical course. To control this …

One of the principal goals of Precision Medicine is to stratify patients by accounting for
individual variability. However, extracting meaningful information from Real-World Data …